A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in their portfolio holdings. The trades indicate a continued interest in ...

Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The ...

Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in Vancouver-based AI drug creation company Absci soared on Wednesday after investment firm Needham & Co ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

Shares of Absci Co. (NASDAQ:ABSI – Get Free Report) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Seven investment ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI companies under $2 billion market cap. It’s clear that AI holds immense promise but it comes ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Absci (NASDAQ:ABSI) stands against other AI ...